Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 11/20 | 0.50 |
| ▸ | ASPH | Q12797 | 5/20 | 0.50 |
| ▸ | KDM8 | Q8N371 | 5/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | AGER | Q15109 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | GABRP | O00591 | 3/20 | 0.42 |
| ▸ | GABRD | O14764 | 3/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.42 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.42 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29860445 | 1.00 | KDM4E (0.50) | KDM4EASPHKDM8MAPTALDH1A1 | |
| SCHEMBL20520334 | 0.86 | KDM4E (0.42) | KDM4EASPHKDM8MAPTALDH1A1 | |
| SCHEMBL22688908 | 0.81 | NAPRT (0.48) | KDM4EASPHKDM8MAPTALDH1A1 | |
| SCHEMBL22688920 | 0.81 | KDM4E (0.47) | KDM4EASPHKDM8MAPTALDH1A1 | |
| Hydrochloric Acid SCHEMBL20239059 | 0.80 | KDM4E (0.61) | KDM4EASPHKDM8MAPTALDH1A1 | |
| SCHEMBL3798200 | 0.79 | KDM4E (0.46) | KDM4EASPHKDM8MAPTALDH1A1 | |
| SCHEMBL29525861 | 0.78 | KDM4E (0.53) | KDM4EASPHKDM8MAPTALDH1A1 | |
| SCHEMBL7080699 | 0.78 | GRM6 (0.41) | KDM4EASPHKDM8MAPTALDH1A1 | |
| SCHEMBL24813521 | 0.78 | HTT (0.42) | KDM4EASPHKDM8MAPTALDH1A1 | |
| SCHEMBL2349928 | 0.78 | KDM4E (0.44) | KDM4EASPHKDM8MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590343-B2 | Corrosion inhibitor composition for magnesium or magnesium alloys | Helmholtz-Zentrum Geesthacht Zentrum für Material-und Küstenforschung GmbH (DE) | 2020-03-17 | — | — | US | claimed |
| EP-3284847-B1 | CORROSION INHIBITOR COMPOSITION FOR MAGNESIUM OR MAGNESIUM ALLOYS | HELMHOLTZ ZENTRUM GEESTHACHT (DE) | 2019-01-02 | — | — | EP | claimed |
| EP-3284847-A1 | CORROSION INHIBITOR COMPOSITION FOR MAGNESIUM OR MAGNESIUM ALLOYS | Helmholtz-Zentrum Geesthacht Zentrum für Material- und Küstenforschung GmbH (DE) | 2018-02-21 | — | — | EP | claimed |
| US-20180044590-A1 | Corrosion Inhibitor Composition for Magnesium or Magnesium Alloys | Helmholtz-Zentrum Geesthacht Zentrum für Material-und Küstenforschung GmbH (DE) | 2018-02-15 | — | — | US | claimed |
| US-20040006103-A1 | Use of chloroquine, hydroxychloroquine and 4 amino-quinolinic derivatives to obtain a drug for the anti retroviral therapy, active towards HIV sensitive strains and towards HIV strains which are resistant to both nucleosidic and non-nucleosidic reverse transcriptase inhibitors and to proteases inhibitors | VALPHARMA S.A. (SM) | 2004-01-08 | — | — | US | claimed |
| EP-1374867-A1 | Use of chloroquine, hydroxychloroquine and 4 amino-quinolinic derivatives to obtain a drug for the anti retroviral therapy, active towards hiv sensitive strains and towards hiv strains which are resistant to both nucleosidic and non-nucleosidic reverse transcriptase inhibitors and to proteases inhibitors | Valpharma S.A. (SM) | 2004-01-02 | — | — | EP | claimed |
| EP-0663399-B1 | Pyridine-2,3-dicarboxylic imides, process for their preparation and their use to control the growth of unwanted plants | BASF AG (DE) | 1998-06-10 | — | — | EP | claimed |
| US-12515207-B2 | Metal-metal bonded ammonia oxidation catalysts | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2026-01-06 | — | — | US | disclosed |
| US-20250276300-A1 | REDUCTION OF MONOMERIC ISOCYANATES BY POROUS MATERIAL | BASF SE (DE) | 2025-09-04 | — | — | US | disclosed |
| EP-4291588-B1 | REDUCTION OF MONOMERIC ISOCYANATES BY POROUS MATERIAL | BASF SE (DE) | 2025-08-20 | — | — | EP | disclosed |
| CN-115368342-B | Fibroblast active protein inhibitor, radionuclide marker, preparation method and application thereof | 西南医科大学附属医院 | 2024-01-23 | — | — | CN | disclosed |
| EP-4291588-A1 | REDUCTION OF MONOMERIC ISOCYANATES BY POROUS MATERIAL | BASF SE (DE) | 2023-12-20 | — | — | EP | disclosed |
| CN-116829611-A | Reduction of monomeric isocyanates by porous materials | 巴斯夫欧洲公司 | 2023-09-29 | — | — | CN | disclosed |
| US-4921530-A | Certain 3,5-pyridine dicarboxylates, their thio analogues having herbicidal activity | MONSANTO COMPANY (US) | 1990-05-01 | — | — | US | disclosed |
| US-4835279-A | 2,6-substituted pyridine compounds | MONSANTO COMPANY (US) | 1989-05-30 | — | — | US | disclosed |
| US-4824954-A | FROM ACETONE DIESTER 4-1AMINO-2,3-BIS/HALOALKYL-3,5-PYRIDINEDICARBOXYLATE | MONSANTO COMPANY (US) | 1989-04-25 | — | — | US | disclosed |
| US-4797149-A | HERBICIDES | MONSANTO COMPANY (US) | 1989-01-10 | — | — | US | disclosed |
| US-4698093-A | POST, PRE EMERGENTS | MONSANTO COMPANY (US) | 1987-10-06 | — | — | US | disclosed |
| EP-0182769-A1 | 2,6-Substituted pyridine compounds | Monsanto Company (US) | 1986-05-28 | — | — | EP | disclosed |
| EP-0181312-A2 | Process for preparation of substituted pyridines | Monsanto Company (US) | 1986-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006103-A1 | Use of chloroquine, hydroxychloroquine and 4 amino-quinolinic derivatives to obtain a drug for the anti retroviral therapy, active towards HIV sensitive strains and towards HIV strains which are resistant to both nucleosidic and non-nucleosidic reverse transcriptase inhibitors and to proteases inhibitors | QTRT1, NQO2, CTSL | KDM4E 600/4885ASPH 402/4885KDM8 365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.